Midwest Orthopedics at Rush, Rush University Medical Center, 1611 West Harrison Street, Suite 300, Chicago, IL 60612, USA.
Am J Sports Med. 2012 Sep;40(9):2015-22. doi: 10.1177/0363546512453292. Epub 2012 Jul 19.
This is an analysis of the prospective Study of the Treatment of Articular Repair (STAR) to evaluate the effectiveness of autologous chondrocyte implantation (ACI) in a subset of adult patients with osteochondritis dissecans (OCD) knee lesions.
Autologous chondrocyte implantation can improve clinical outcomes in patients with at least 1 chronic OCD lesion of the knee who failed a previous non-ACI cartilage repair treatment.
Case series; Level of evidence, 4.
Forty patients with at least one failed non-ACI treatment for an OCD knee lesion received ACI in a multicenter study. The modified Cincinnati Knee Rating System, the Knee injury and Osteoarthritis Outcome Score (KOOS), and the Short-Form 36 Health Survey (SF-36) were used to assess patient outcomes at baseline and periodically to 48 months. Treatment failures, serious adverse events, and subsequent surgical procedures were recorded.
Thirty-two (80%) patients completed the 48-month study. Autologous chondrocyte implantation treatment was successful in 85% of patients. Mean (± standard deviation) overall knee condition score (modified Cincinnati) was 3.1 ± 1.1 at baseline and 6.8 ± 2.0 at month 48. Clinically and statistically significant (P < .001) mean improvements from baseline to month 48 for the KOOS were as follows: 51.5 to 79.5 (pain), 54.8 to 77.9 (symptoms), 27.5 to 63.6 (sports and recreation ability), 63.5 to 86.7 (activities of daily living), and 21.9 to 59.6 (knee-related quality of life). The mean improvement (P < .001) in overall health assessed by the SF-36 was 35.4 to 45.5. Thirty-five percent (n = 14/40) of patients had a subsequent surgical procedure, most frequently debridement of the cartilage lesion. Treatment failure occurred in 6 of 32 (19%) patients.
Patients with OCD of the knee had statistically significant pain reduction and functional improvement for up to 48 months after ACI, despite the complexity and severity of the osteochondral lesions.
这是一项前瞻性研究,即关节修复治疗研究(STAR),旨在评估自体软骨细胞移植(ACI)在患有骺软骨骨软骨病(OCD)膝关节病变的部分成年患者中的疗效。
自体软骨细胞移植可改善既往非 ACI 软骨修复治疗失败的膝关节 OCD 慢性病变患者的临床结果。
病例系列;证据水平,4 级。
在一项多中心研究中,40 例至少有 1 次接受非 ACI 治疗失败的 OCD 膝关节病变患者接受了 ACI。采用改良辛辛那提膝关节评分系统、膝关节损伤和骨关节炎结果评分(KOOS)和健康调查简表 36 项(SF-36)评估患者的基线和 48 个月的治疗结果。记录治疗失败、严重不良事件和后续手术。
32 例(80%)患者完成了 48 个月的研究。ACI 治疗成功率为 85%。平均(±标准差)总体膝关节状况评分(改良辛辛那提)为基线时的 3.1 ± 1.1,48 个月时的 6.8 ± 2.0。KOOS 从基线到 48 个月的平均改善具有临床和统计学意义(P<.001),分别为:疼痛从 51.5 至 79.5,症状从 54.8 至 77.9,运动和娱乐能力从 27.5 至 63.6,日常生活活动从 63.5 至 86.7,膝关节相关生活质量从 21.9 至 59.6。SF-36 评估的总体健康状况的平均改善(P<.001)为 35.4 至 45.5。35%(n=14/40)的患者接受了后续手术,最常见的是软骨病变清创术。32 例(19%)患者中有 6 例(6 例)治疗失败。
尽管骨软骨病变复杂且严重,但 ACI 后膝关节 OCD 患者的疼痛减轻和功能改善在 48 个月内具有统计学意义。